Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | EXEC. VP AND CLO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 105,272 |
Ending reported balance
After 2026-10-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04 | Direct | 2,267 |
Reported balance
After 2026-10-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025. F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2023 Filed Jan 11, 2023 23:14 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 835 | $41.66 | $34,782.93 |
DisclosureSEC source: 0001415889-23-000837 · form4-01112023_110127.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,275 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:56 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 36,250 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000692 · form4-01092023_090131.xml · derivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,250 Underlying: Common Stock · 36,250 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:56 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000692 · form4-01092023_090131.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,110 F1 · shares: Restricted stock units granted on January 5, 2023 that vest in four equal installments over four years, commencing on January 5, 2024. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 289 | $30.86 Strike: $30.86 | $8,918.54 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · derivative · entry 12 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,923 Underlying: Common Stock · 289 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10 | $30.86 Strike: $30.86 | $308.60 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · derivative · entry 11 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,212 Underlying: Common Stock · 10 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 289 | $55.04 | $15,907.43 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · nonDerivative · entry 8 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.00 to $55.57 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 289 | $30.86 | $8,918.54 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · nonDerivative · entry 7 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10 | $55.45 | $554.50 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · nonDerivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| October 18, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 10 | $30.86 | $308.60 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · nonDerivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,402 | $30.86 Strike: $30.86 | $197,565.72 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · derivative · entry 10 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,222 Underlying: Common Stock · 6,402 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $30.86 Strike: $30.86 | $6,172.00 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · derivative · entry 9 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,624 Underlying: Common Stock · 200 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,402 | $55.00 | $352,110.00 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,402 | $30.86 | $197,565.72 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 200 | $55.00 | $11,000.00 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 20:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 200 | $30.86 | $6,172.00 |
DisclosureSEC source: 0001415889-22-010716 · form4-10192022_011001.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300 | $30.86 Strike: $30.86 | $9,258.00 |
DisclosureSEC source: 0001415889-22-009867 · form4-09222022_010902.xml · derivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,824 Underlying: Common Stock · 69,124 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 876 | $30.86 Strike: $30.86 | $27,033.36 |
DisclosureSEC source: 0001415889-22-009867 · form4-09222022_010902.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,124 Underlying: Common Stock · 70,000 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 300 | $55.00 | $16,500.00 |
DisclosureSEC source: 0001415889-22-009867 · form4-09222022_010902.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 300 | $30.86 | $9,258.00 |
DisclosureSEC source: 0001415889-22-009867 · form4-09222022_010902.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 876 | $55.00 | $48,180.00 |
DisclosureSEC source: 0001415889-22-009867 · form4-09222022_010902.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| September 20, 2022 Filed Sep 22, 2022 20:38 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 876 | $30.86 | $27,033.36 |
DisclosureSEC source: 0001415889-22-009867 · form4-09222022_010902.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,986 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,276 | $11.23 Strike: $11.23 | $25,559.48 |
DisclosureSEC source: 0001415889-22-004082 · form4-04152022_010456.xml · derivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,276 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,276 | $45.17 | $102,811.47 |
DisclosureSEC source: 0001415889-22-004082 · form4-04152022_010456.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.35 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 20:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,276 | $11.23 | $25,559.48 |
DisclosureSEC source: 0001415889-22-004082 · form4-04152022_010456.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 20:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5 | $11.23 Strike: $11.23 | $56.15 |
DisclosureSEC source: 0001415889-22-003935 · form4-04072022_010455.xml · derivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,276 Underlying: Common Stock · 5 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F2 · derivative.exercise_date: Currently exercisable. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 20:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5 | $45.00 | $225.00 |
DisclosureSEC source: 0001415889-22-003935 · form4-04072022_010455.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 20:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 5 | $11.23 | $56.15 |
DisclosureSEC source: 0001415889-22-003935 · form4-04072022_010455.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,653 | $18.01 Strike: $18.01 | $281,910.53 |
DisclosureSEC source: 0001179110-22-001094 · edgar.xml · derivative · entry 6 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,653 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,282 | $11.23 Strike: $11.23 | $25,626.86 |
DisclosureSEC source: 0001179110-22-001094 · edgar.xml · derivative · entry 5 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,281 Underlying: Common Stock · 2,282 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 15,653 | $45.03 | $704,807.63 |
DisclosureSEC source: 0001179110-22-001094 · edgar.xml · nonDerivative · entry 4 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.01 to $45.04 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 15,653 | $18.01 | $281,910.53 |
DisclosureSEC source: 0001179110-22-001094 · edgar.xml · nonDerivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,282 | $45.03 | $102,751.61 |
DisclosureSEC source: 0001179110-22-001094 · edgar.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.01 to $45.04 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 21:11 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,282 | $11.23 | $25,626.86 |
DisclosureSEC source: 0001179110-22-001094 · edgar.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 21:57 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 779 | $40.00 | $31,161.56 |
DisclosureSEC source: 0001179110-22-000836 · edgar.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,110 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 29, 2020 grant of 10,200 RSUs. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:19 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000399 · edgar.xml · derivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2032-01-06 F3 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:19 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 14,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000399 · edgar.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,889 F2 · shares: Restricted stock units granted on January 7, 2022 that vest in four equal installments over four years, commencing on January 7, 2023. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:19 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 885 | $38.53 | $34,094.63 |
DisclosureSEC source: 0001179110-22-000399 · edgar.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,489 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,363 | $18.01 Strike: $18.01 | $60,567.63 |
DisclosureSEC source: 0001179110-21-008584 · edgar.xml · derivative · entry 3 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,653 Underlying: Common Stock · 3,363 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F3 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,363 | $45.01 | $151,375.36 |
DisclosureSEC source: 0001179110-21-008584 · edgar.xml · nonDerivative · entry 2 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.04 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 20:06 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,363 | $18.01 | $60,567.63 |
DisclosureSEC source: 0001179110-21-008584 · edgar.xml · nonDerivative · entry 1 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 244 | $18.01 Strike: $18.01 | $4,394.44 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 30 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,016 Underlying: Common Stock · 244 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F10 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 227 | $18.01 Strike: $18.01 | $4,088.27 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 29 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,260 Underlying: Common Stock · 227 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F10 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 410 | $18.01 Strike: $18.01 | $7,384.10 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 28 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,487 Underlying: Common Stock · 410 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F10 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 548 | $18.01 Strike: $18.01 | $9,869.48 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · derivative · entry 27 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,897 Underlying: Common Stock · 548 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F10 · derivative.exercise_date: This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 244 | $45.00 | $10,980.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 20 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 244 | $18.01 | $4,394.44 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 19 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 227 | $45.00 | $10,215.00 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 18 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 227 | $18.01 | $4,088.27 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 17 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,601 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 410 | $45.00 | $18,450.82 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 16 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,374 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $45.00 to $45.01 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| July 09, 2021 Filed Jul 12, 2021 20:26 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 410 | $18.01 | $7,384.10 |
DisclosureSEC source: 0001179110-21-007468 · edgar.xml · nonDerivative · entry 15 Boulding Mark Elliott · CIK 0001578852 · Exec. VP and CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on March 10, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.